See more : Hydrogène de France Société anonyme (HDF.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Calliditas Therapeutics AB (publ) (CLTEF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Carrier Global Corporation (4PN.DE) Income Statement Analysis – Financial Results
- Climate Real Impact Solutions II Acquisition Corporation (CLIM-UN) Income Statement Analysis – Financial Results
- IKIO Lighting Limited (IKIO.BO) Income Statement Analysis – Financial Results
- Beijing Haohua Energy Resource Co., Ltd. (601101.SS) Income Statement Analysis – Financial Results
- MLG Oz Limited (MLG.AX) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CLTEF)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 76.95M | 25.35M | 106.24K | 19.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 75.49M | 25.35M | 106.24K | 19.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 39.75M | 39.52M | 29.34M | 16.00M | 11.20M | 6.30M | 4.42M | 4.37M |
| General & Administrative | 24.82M | 23.15M | 12.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 49.38M | 19.85M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.25M | 43.14M | 17.23M | 6.71M | 3.51M | 10.31M | 6.19M | 6.07M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 111.93M | 81.33M | 53.14M | 23.27M | 14.90M | 10.31M | 6.14M | 6.04M |
| Cost & Expenses | 113.39M | 81.33M | 53.14M | 23.27M | 14.90M | 10.31M | 6.14M | 6.04M |
| Interest Income | 2.80M | 774.50K | 18.72K | 64.18K | 225.65 | 273.55K | 110.45K | 1.07K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 201.85K | 82.58K | 4.50K | 4.70K | 5.75K | 6.22K | 12.30K | 13.15K |
| EBITDA | -412.70M | -494.12M | -382.18M | -27.84M | -130.34M | -84.60M | -56.41M | -51.28M |
| EBITDA Ratio | -49.42% | -225.69% | -43,728.51% | -15.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -38.23M | -57.30M | -46.46M | -2.98M | -14.71M | -10.32M | -6.21M | -6.09M |
| Operating Income Ratio | -49.68% | -226.02% | -43,732.75% | -15.08% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.53M | 11.08M | -56.43M | -4.48M | 433.00K | -2.29M | -892.00K | -103.00K |
| Income Before Tax | -39.24M | -56.75M | -53.02M | -3.47M | -14.90M | -10.58M | -6.25M | -6.04M |
| Income Before Tax Ratio | -50.99% | -223.84% | -49,903.28% | -17.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 273.25K | 424.06K | 43.76K | 8.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -39.51M | -55.31M | -52.69M | -3.48M | -14.90M | -10.58M | -6.25M | -6.04M |
| Net Income Ratio | -51.35% | -218.14% | -49,599.27% | -17.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -1.09 | -1.17 | -0.09 | -0.57 | -0.71 | -0.50 | -0.59 |
| EPS Diluted | -0.75 | -1.09 | -1.17 | -0.09 | -0.57 | -0.71 | -0.50 | -0.59 |
| Weighted Avg Shares Out | 52.99M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 12.46M | 10.30M |
| Weighted Avg Shares Out (Dil) | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 12.46M | 10.30M |
Source: https://incomestatements.info
Category: Stock Reports